We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

228 hedge funds and large institutions have $2.18B invested in Kiniksa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 76 increasing their positions, 85 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,984% more call options, than puts

Call options by funds: $51.5M | Put options by funds: $1.26M

23% more capital invested

Capital invested by funds: $1.77B → $2.18B (+$410M)

21% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 34

3.79% more ownership

Funds ownership: 95.16% → 98.95% (+3.8%)

2% more funds holding

Funds holding: 224 → 228 (+4)

11% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 85

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
228
Holders Change
+4
Holders Change %
+1.79%
% of All Funds
2.81%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
41
Increased
76
Reduced
85
Closed
34
Calls
$51.5M
Puts
$1.26M
Net Calls
+$50.3M
Net Calls Change
-$11.5M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$230M
2
Bank of America
Bank of America
North Carolina
+$22.4M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$22.1M
4
RCMNY
Rubric Capital Management (New York)
New York
+$18.7M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$15.1M

Top Sellers

1
FFM
Fairmount Funds Management
Pennsylvania
-$54.4M
2
Goldman Sachs
Goldman Sachs
New York
-$29M
3
PHP
Parkman Healthcare Partners
Connecticut
-$18M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$16.7M
5
Morgan Stanley
Morgan Stanley
New York
-$16M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
76
Fieldview Capital Management
Michigan
$2.46M +$2.26M +51,072 New
Charles Schwab
77
Charles Schwab
California
$2.42M -$586K -13,231 -21%
OCA
78
OpenArc Corporate Advisory
Georgia
$2.33M +$642K +14,491 +43%
UBS AM
79
UBS AM
Illinois
$2.14M +$94K +2,123 +5%
Geode Capital Management
80
Geode Capital Management
Massachusetts
$2.13M -$64.8K -1,463 -3%
Cerity Partners
81
Cerity Partners
New York
$2.1M +$21.8K +493 +1%
SSA
82
Schonfeld Strategic Advisors
New York
$2.1M -$904K -20,396 -32%
JG
83
Jain Global
New York
$2.07M +$497K +11,221 +35%
IC
84
IEQ Capital
California
$2.07M -$217K -4,891 -10%
California State Teachers Retirement System (CalSTRS)
85
California State Teachers Retirement System (CalSTRS)
California
$2.02M +$464K +10,477 +33%
Baird Financial Group
86
Baird Financial Group
Wisconsin
$1.94M -$88.1K -1,988 -5%
JF
87
Jump Financial
Illinois
$1.91M -$2.29M -51,694 -57%
Northern Trust
88
Northern Trust
Illinois
$1.78M -$1.04M -23,373 -39%
II
89
Inspire Investing
Idaho
$1.7M +$1.56M +35,271 New
Barclays
90
Barclays
United Kingdom
$1.64M +$1.31M +29,575 +646%
Citigroup
91
Citigroup
New York
$1.62M +$1.42M +32,021 +1,891%
VFT
92
Vanguard Fiduciary Trust
Pennsylvania
$1.55M +$1.42M +32,096 New
Stifel Financial
93
Stifel Financial
Missouri
$1.54M +$1.42M +31,951 New
Ameriprise
94
Ameriprise
Minnesota
$1.53M -$16K -361 -1%
LCG
95
Lisanti Capital Growth
New York
$1.5M +$1.38M +31,065 New
Raymond James Financial
96
Raymond James Financial
Florida
$1.43M -$802K -18,103 -37%
AGP
97
Artia Global Partners
Florida
$1.41M – – –
Ohio Public Employees Retirement System (OPERS)
98
Ohio Public Employees Retirement System (OPERS)
Ohio
$1.39M – – –
Hudson Bay Capital Management
99
Hudson Bay Capital Management
Connecticut
$1.33M +$1.23M +27,670 New
Invesco
100
Invesco
Georgia
$1.33M -$207K -4,678 -14%
2 3
4
5 6

KNSA Hedge Fund Activity: Q1 2026 in Review

228 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2026, worth a combined $2.18B — up 23% from $1.77B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new KNSA positions and 34 closed out — a net gain of 7 holders — while 76 added to existing stakes and 85 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $230M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $54.4M sold.

  • 228 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2026, up from 224 in Q4 2025.
  • Funds reported $2.18B of Kiniksa Pharmaceuticals stock for Q1 2026, up 23% quarter-over-quarter.
  • 41 funds opened new Kiniksa Pharmaceuticals positions in Q1 2026 and 34 closed out, a net change of +7 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q1 2026 was Fidelity Investments, an estimated $230M added.
  • The largest Kiniksa Pharmaceuticals seller in Q1 2026 was Fairmount Funds Management, an estimated $54.4M sold.

Based on aggregated 13F filings for Q1 2026.